Singapore - English - HSA (Health Sciences Authority)

kyowa kirin asia pacific pte. ltd. - burosumab - injection, solution - burosumab 30 mg/ml

Singapore - English - HSA (Health Sciences Authority)

kyowa kirin asia pacific pte. ltd. - burosumab - injection, solution - burosumab 10 mg/ml

Australia - English - Department of Health (Therapeutic Goods Administration)

kyowa kirin australia pty ltd - burosumab, quantity: 30 mg - injection, solution - excipient ingredients: sorbitol; histidine; methionine; polysorbate 80; water for injections; hydrochloric acid - crysvita (burosumab) is indicated for the treatment of x-linked hypophosphataemia (xlh) in adults, adolescents and children 1 year of age or older.

Australia - English - Department of Health (Therapeutic Goods Administration)

kyowa kirin australia pty ltd - burosumab, quantity: 20 mg - injection, solution - excipient ingredients: sorbitol; histidine; methionine; polysorbate 80; water for injections; hydrochloric acid - crysvita (burosumab) is indicated for the treatment of x-linked hypophosphataemia (xlh) in adults, adolescents and children 1 year of age or older.

Australia - English - Department of Health (Therapeutic Goods Administration)

kyowa kirin australia pty ltd - burosumab, quantity: 10 mg - injection, solution - excipient ingredients: sorbitol; histidine; methionine; polysorbate 80; water for injections; hydrochloric acid - crysvita (burosumab) is indicated for the treatment of x-linked hypophosphataemia (xlh) in adults, adolescents and children 1 year of age or older.